TET2 and chronic myelogenous leukemia, BCR-ABL1 positive: Most recently, a NGS-based screen of 92 myeloid-associated genes in 300 serial samples from 100 CP CML patients at diagnosis and after TKI therapy showed evidence of DNMT3A, TET2, ASXL1, BCOR and CREBBP mutations in both diagnosis and follow-up samples, despite response to TKI therapy and BCR-ABL1 transcript clearance [49].